The ups and downs of life as a small-cap med-tech company go on for TearLab (TEAR).
There's still plenty of controversy regarding this name, not the least
of which is a mixed bag of clinical papers on the company's osmolarity
system, but strong system bookings certainly haven't done the stock any
harm.
Most recently, though, the company announced the appointment of Seph Jensen, a long-time Alcon (part of Novartis (NVS))
veteran, as the company's new President and COO. Not only can Jensen
bring experience on the device side of ophthalmology to the company and
help the company appropriately build its sales/marketing efforts, but
the addition of an industry veteran from a well-known company helps the
image of TearLab as well.
Please follow this link to continue:
TearLab Builds Its Bench
No comments:
Post a Comment